Human Major Histocompatibility Complex Class II-restricted T Cell Responses in Transgenic Mice

By Andrea Woods,* Howard Y. Chen,† Myrna E. Trumbauer,† Anna Sirotina,§ Rich Cummings,¶ and Dennis M. Zaller*

From the Departments of *Molecular Immunology, †Genetics & Molecular Biology, §Immunology, and ¶Biophysical Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065

Summary
Transgenic mice expressing human major histocompatibility complex (MHC) class II molecules would provide a valuable model system for studying human immunology. However, attempts to obtain human class II-restricted T cell responses in such transgenic mice have had only limited success, possibly due to an inability of mouse CD4 to interact efficiently with human MHC class II molecules. To circumvent this problem, we constructed recombinant MHC class II genes in which the peptide-binding domain was derived from human DR sequences whereas the CD4-binding domain was derived from mouse I-E sequences. Purified chimeric human/mouse MHC class II molecules were capable of specifically binding DR-restricted peptides. Human B cell transformants that expressed these chimeric MHC class II molecules could present peptide antigens to human T cell clones. Expression of these chimeric class II molecules in transgenic mice led to the intrathymic deletion of T cells expressing superantigen-reactive Vβ gene segments, indicating that the chimeric class II molecules could influence the selection of the mouse T cell repertoire. These transgenic mice were fully capable of mounting human DR-restricted immune responses after challenge with peptide or whole protein antigens. Thus, the chimeric class II molecules can serve as functional antigen presentation molecules in vivo. In addition, transgenic mice expressing chimeric class II molecules could be used to generate antigen-specific mouse T cell hybridomas that were capable of interacting with human antigen-presenting cells.

MHC class II proteins are cell surface heterodimers composed of a nearly invariant α chain and a highly polymorphic β chain. The primary function of these molecules is to present peptide fragments derived from processed antigens to CD4-bearing T cells. Interactions between MHC class II–peptide complexes and TCRs play a central role in the selection of the T cell repertoire and in the elicitation of an immune response. The inheritance of particular MHC class II alleles is genetically associated with susceptibility to certain autoimmune diseases such as type 1 diabetes and rheumatoid arthritis (1, 2). The basis of the association between MHC class II genes and autoimmune disease is not known, but could be due to several immunological mechanisms. Polymorphic amino acid residues in the class II peptide-binding groove might differentially bind potential autoantigens. Alternatively, the expression of particular MHC class II alleles might dictate whether autoreactive T cells reach functional maturity during development in the thymus. Another explanation that has been proposed for HLA disease associations is molecular mimicry between environmental pathogens and MHC class II proteins (3, 4). Sequence homologies between CMV proteins (5), EBV proteins (6, 7), and disease-associated MHC class II molecules have been described, although the mechanisms by which these homologies could lead to autoimmune disease are not clear.

A model system in which human MHC class II molecules were expressed in transgenic mice would be of great benefit for studying the role of these molecules in the induction of autoimmune disease. However, previous attempts to generate human class II–restricted T cells responses in such transgenic mice have had only limited success (8, 9). One possible reason for this is an inability of mouse CD4 to interact efficiently with human MHC class II molecules (10–13). This xenogeneic barrier would be expected to result in inefficient interactions between mouse CD4-positive T cells and human class II–expressing APCs in the transgenic mice. It seemed reasonable that this barrier could be overcome by employing chimeric human/mouse MHC class II molecules in which the CD4-binding domain of the human protein is replaced by the corresponding domain of the mouse protein. Experiments using human class II molecules which had been altered by exon shuffling (12, 13) or point mutation (14) have identified a region on the β2 domain of human class II molecules that is involved in binding to CD4. Direct binding studies using
soluble CD4 and synthetic peptides derived from the human class II β2 domain have confirmed these observations (15). These studies did not rule out the possibility of additional interactions between CD4 and regions on the MHC class II α chain.

In this report, we describe transgenic mice expressing recombinant MHC class II molecules in which the α1 and β1 domains of mouse I-E^d were replaced by the corresponding domains of human DRB1*0401 (DR4 Dw4) molecules. These molecules should be capable of presenting human class II-restricted peptides to mouse CD4-positive cells. DR4 Dw4 was chosen because its expression has been associated with susceptibility to autoimmune disease in humans. The inheritance of MHC haplotypes containing DR4 Dw4 is associated with an increased risk of developing rheumatoid arthritis (16-22). In addition, the relative risk of developing type 1 diabetes is highest in individuals that express DR4 Dw4 along with the A3 and DRB1*0401 molecules (2.5 riM) or purified chimeric MHC class II molecules

**Materials and Methods**

**Mice.** (C57BL/6 × SJL/J) F2 mice and B10.M/Sn H-2^b mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Intercrosses and backcrosses of transgenic founders to B10.M/Sn H-2^b were performed in the Merck Research Laboratories animal facility under sterile, specific pathogen-free conditions. The experiments described in this report were performed with H-2^b homozygous mice from the third or fourth backcross generations.

**Chimeric MHC Class II Gene Constructions.** For the chimeric α chain, an 8.4-kb HindIII fragment containing the Eo gene was subcloned into a modified Bluescript vector in which the EcoRI and BamHI sites in the polylinker were destroyed by enzyme digestion followed by extension with Klenow polymerase. This plasmid was digested with EcoRI and BamHI to remove a 1.1-kb fragment containing the second exon of the Eo gene. A 696-bp PCR product was obtained by amplification of Priess DNA with primers flanking the second exon of the DR α1 gene (5'-GGG-GGAATTC-TGG-CCTAAG-TGATATTAA-A3CC-CCC-GG-G-3' and 5'-GGG-GGAATTCC-TTGATATTAA-A3CC-CCC-GG-G-3') and then cloned into this plasmid. An 8.0-kb HindIII fragment was isolated from the final plasmid subclone for microinjection into fertilized eggs. For the chimeric β chain, a 2.2-kb BamHI/HindIII fragment containing the first exon of the Eβ^d gene was subcloned into the pACYC184 vector and then altered by site-directed mutagenesis so that three nucleotides of the exon were changed to the corresponding nucleotides of the first exon of DR4 Dw4. This was accomplished by PCR amplification using a primer flanking the BamHI site of the insert (5'-GAT-ATA-GGC-GCC-AGC-CGC-ACC-T3') and a primer that spanned an ApaI site in the first intron (5'-TGA-GGT-GTG-CCA-TTA-GCC-CCC-GTG-CCG-ACC-AAA-GC-3'). The PCR product was ligated back into a BamHI/Apal partial digest of the plasmid subclone. A 1.9-kb EcoRI/BamHI fragment containing the altered first exon was then used to replace the corresponding fragment of plasmid clone that contained a 6.6-kb Clal/EcoRI insert encompassing the 5' end of the Eβ^d gene. Next, a 1.1-kb BamHI/HindIII fragment containing the DR4 Dw4 β chain second exon was isolated from the λ713 phage clone (26). The ends of this fragment were converted to EcoRI and BamHI and ligated to the 6.6-kb Clal/EcoRI fragment described above, along with a 5.9-kb Bluescript subclone that had an insert containing exons 3–6 of the Eβ^d gene. A 10.6-kb XmnI/NsiI fragment was isolated from the final plasmid subclone for microinjection into fertilized eggs.

**Cell Lines.** All cell lines were maintained in RPMI medium supplemented with 10% FCS. The B cell line, MUD45, was generated by the fusion of LPS-activated B10.PL spleen cells to the A20 B-lymphoma line (27). As a result of chromosomal segregation, MUD45 cells express the H-2^D MHC haplotype from B10.PL, but not the H-2^D MHC haplotype from the A20 cells. Chimeric MHC class II genes and the pSV2neo vector were cotransfected into MUD45 cells by electroporation using a gene pulser (Bio-Rad Laboratories, Richmond, CA). Stable transformants were selected by culturing at limiting dilution with 1 mg/ml G418. The 17-11 human T cell clone was obtained from the ImmunoLogic Pharmaceutical Corporation (Palo Alto, CA), and is specific for HA(307-319) presented in the context of DR4 Dw4.

**Flow Cytometry.** The mAbs used for detecting class II molecules were as follows (specificity is indicated in parentheses): LB3.1 (DRα1), L243 (DRα1), L227 (DRβ1), MTM39.6 (DRβ1), MTM23.4 (DRα1), MTM16.7 (DRα1/β1), MTM12.1 (DRα1/β1), MTM45.6 (DRβ1), and Y3P (α-A). LB3.1 and Y3P were purified from cell culture supernatants. L243 was purchased from Becton Dickinson & Co. (San Jose, CA). The MTM series of Abs were gifts from the ImmunoLogic Pharmaceutical Corporation. The class II domain specificity of these antibodies was determined by comparison of single and double chain transformants expressing the chimeric MHC class II gene products. The mAbs used for detecting T cell populations were as follows: P3.21 (Vβ8.2), RR3-15 (Vβ11), RR4-7 (Vβ6), MR5-2 (Vβ8.1/Vβ8.2), B20.6 (Vα2), and 500AA2 (CD3). These Abs were either purified from cell culture supernatants or purchased from PharMingen (San Diego, CA). Protein A-purified antibodies were labeled using NHS-biotin (Pierce, Rockford, IL) according to the manufacturer's directions. The fluorosecin-conjugated mAbs used to identify H-2^b homozygous mice were KH95 (D^b), KH43 (D^b), 15-5-5 (D^b), 7-16.17 (A^b, A^d), and Y3P (A^b). KH95, KH43, 15-5-5, and 7-16.17 were purchased from PharMingen. PBLs from H-2^b homozygous mice were stained with 15-5-5 and Y3P, but not with KH95, KH43, and 7-16.17. For single colored stains, 5 × 10^6 cells were incubated with FITC-conjugated Abs or sequentially incubated with biotin-conjugated Abs followed by FITC-conjugated streptavidin (Fisher Scientific Co., Pittsburgh, PA). For two-colored stains, cells were sequentially incubated with FITC-conjugated first-step Ab, biotin-conjugated second-step Ab, and PE-conjugated streptavidin (Fisher Scientific Co.). Lymphocytes were purified from peripheral blood, spleen, or lymph nodes by density gradient centrifugation using Lympholyte M (Cedarlane Laboratories, Westbury, NY). Stained cells were analyzed using a FACScan (Becton Dickinson & Co.).

**MHC Class II/Peptide Binding Assays.** Purified native DR4 Dw4 molecules (2.5 nM) or purified chimeric MHC class II molecules (1.25 nM) were incubated for 18 h at 37°C with peptides that were labeled at the NH2 terminus with biotin. Bound peptides were separated from free peptides by immobilizing the MHC class II molecules on microtiter plates incubated overnight at 4°C with 10 μg/ml of affinity purified L227 mAb. Bound biotinylated peptides were detected by sequential incubations with streptavidin conjugated mAbs used to identify H-2^b homozygous mice were stained with 15-5-5 and Y3P, but not with KH95, KH43, and 7-16.17. For single colored stains, 5 × 10^6 cells were incubated with FITC-conjugated Abs or sequentially incubated with biotin-conjugated Abs followed by FITC-conjugated streptavidin (Fisher Scientific Co., Pittsburgh, PA). For two-colored stains, cells were sequentially incubated with FITC-conjugated first-step Ab, biotin-conjugated second-step Ab, and PE-conjugated streptavidin (Fisher Scientific Co.). Lymphocytes were purified from peripheral blood, spleen, or lymph nodes by density gradient centrifugation using Lympholyte M (Cedarlane Laboratories, Westbury, NY). Stained cells were analyzed using a FACScan (Becton Dickinson & Co.).

**T Cell Proliferation Assays.** Mice were immunized in the hind footpads with 50 nmol of antigen emulsified in CFA. Lympho-
cytes were isolated from popliteal, inguinal, and paraaortic lymph nodes 10 d after immunization. 4 × 10^6 cells were then cultured in microtiter plates for 4 d in RPMI/10% FCS with serial dilutions of antigen. For human T cell clones, 3 × 10^4 T cells and 10^4 glutaraldehyde-fixed APCs were incubated for 2 d with serial dilutions of antigen. 1 μCi of [3H]thymidine was added to the wells during the last 16 h of culture. Plates were then harvested and counts per minute was determined by liquid scintillation counting.

T Cell Hybridomas. Lymph node cells from immunized mice were cultured for 3 d in the presence of 100 μM of antigen. Live cells were purified over lympholyte M gradients and fused to a BW3147 variant cell line (28). Hybridomas were selected in culture medium supplemented with HAT. The specificity of the hybridomas were assessed in IL-2 release assays. Single cell clones were obtained by culture a limiting dilution.

IL2 Release Assays. Hybridoma cells and APCs were cocultured overnight with serial dilutions of antigen in flat-bottom microtiter plates. Supernatants were then transferred to culture wells containing 5 × 10^4 HT-2 indicator cells. The HT-2 cells were then incubated for 24 h with 1 μCi of [3H]thymidine added during the last 5 h of culture. Plates were harvested and counts per minute was determined by liquid scintillation counting.

Results

Generation of Chimeric Human/Mouse MHC Class II Molecules. Mouse MHC class II Eα and Eβ chain genes (E^d) were genetically engineered to encode proteins in which the α1 (amino acids 1–85) and the β1 domains (amino acids 1–96) were replaced by the corresponding amino acids of the human MHC class II protein, DR4Dw4 (Fig. 1). In the resulting chimeric MHC class II molecules, the peptide-binding domain is derived from human DR4Dw4 sequences, whereas the putative CD4-binding domain is derived from mouse E^d sequences. The promoter regions that lie upstream of the recombinant MHC class II genes were derived from mouse sequences to ensure proper tissue-specific expression in mouse cells (29, 30).

The α and β gene constructions were cotransfected into the B-lymphoma line, MUD45 (see Materials and Methods). Stable transformants were analyzed by flow cytometry with a panel of eight mAbs specific for DR α1 and/or β1 domains. All mAbs that were tested bound to the cell surface of the transformants, suggesting that the chimeric MHC class II molecules were folded into a proper conformation (data not shown). Analysis of cells singly transfected with either the α or the β chain gene construction indicated that heterodimers could form between Eα and the chimeric β chain and between Eβ and the chimeric α chain.

Characterization of Chimeric MHC Class II Molecules. The ability of chimeric MHC class II molecules to bind DR-restricted peptides was evaluated. Cell lysates from the stable B cell transformants were passed over an affinity column containing the mAb LB3.1, which binds to the α1 domain of DR heterodimers. Chimeric α/β heterodimers as well as chimeric α/Eβ heterodimers are copurified using this affinity column. The purified molecules were incubated with labeled peptides and then immobilized on microtiter plates coated with the DR β1-specific mAb, L227. This assay measures the ability of peptides to bind only to chimeric α/β heterodimers since the copurified chimeric α/Eβ heterodimers are not recognized by L227. A synthetic peptide derived from influenza virus hemagglutinin, HA(307-319), was capable of binding to chimeric MHC class II molecules (Fig. 2). Binding was not observed for OVA (323-339), a peptide that does not bind to DR4Dw4. Specific binding was also observed with three other DR-restricted synthetic peptides: myelin basic protein (90-102), heat shock protein (2-14), and influenza nucleoprotein (383-395). The chimeric MHC class II molecules bound peptides with similar affinities to those of native DR4Dw4 molecules purified from the human B cell line, Priess.

The chimeric α and β gene constructions were also cotransfected into the human B cell line, IBW4, which does not express DR4Dw4. The resulting stable transformants acquired the ability to present antigen to DR4Dw4-restricted human T cell clones (Fig. 3). Thus, the chimeric MHC class II molecules are capable of binding DR4Dw4-restricted peptides and of interacting with DR4Dw4-restricted TCRs.

Generation of Transgenic Mice that Express Chimeric MHC Class II Molecules. The chimeric α and β chain genes were coinfected into fertilized eggs derived from (C57BL/6 × SJL/J)F2 mice. Nine transgenic founders that had both transgenes integrated into the germline, two founders that contained only the β chain transgene, and one founder that contained only the α chain transgene were obtained. The founders were intercrossed with mice from the B10.M strain which expresses an H-2^d MHC haplotype. H-2^d homozygous mice do not have endogenous Eα or Eβ chains because of mutations in the relevant MHC class II genes (31, 32). F1 transgenic mice were then backcrossed to B10.M. H-2^d
the expressed MHC class II haplotype of each APC line is shown. The APCs used were Priess (DR4Dw4 positive), IBW4 (DR4Dw4 negative, DR1 positive), and IBW4 transformed with chimeric MHC class II genes (DR4Dw4 negative, DR1 positive, chimeric class II positive).

Figure 2. Chimeric MHC class II molecules can bind DR4Dw4-restricted peptides. Binding assays were performed with native DR4Dw4 molecules purified from Priess cells and with chimeric MHC class II molecules purified from mouse B-lymphoma transformants. A peptide that binds to DR4Dw4 (HA [307-319]) and a peptide that does not bind to DR4Dw4 (OVA [323-339]) were used as ligands in the binding assays. Maximum signals were 173,476 fluorescent units for the DR4Dw4 molecules and 53,503 fluorescent units for the chimeric MHC class II molecules.

Figure 3. Chimeric MHC class II molecules can present antigen to a DR4Dw4-restricted human T cell clone. Proliferative responses of an HA(307-319)-specific, DR4Dw4-restricted human T cell clone, 17-11, are shown after culture with or without various glutaraldehyde-fixed APCs. The APCs used were Priess (DR4Dw4 positive), IBW4 (DR4Dw4 negative, DR1 positive), and IBW4 transformed with chimeric MHC class II genes (DR4Dw4 negative, DR1 positive, chimeric class II positive).
class II molecules. In addition, the response to purified protein derivative (PPD) in the transgenic mice was partially inhibited by LB3.1 (Fig. 6 B). This indicates that the chimeric MHC class II molecules can serve as restricting elements in the immune response to mycobacterial protein antigens.

**Generation of DR4Dw4-restricted, Antigen-specific Mouse T Cell Hybridomas.**

It has not been possible to generate stable human T cell hybridomas due, at least in part, to the lack of an appropriate fusion partner. The transgenic mice described in this report offer an alternative means of raising human class II-restricted T cell hybridomas. T cells from HA(307-319)-immunized mice were fused to a TCR-negative variant of the BW5147 thymoma line (28). T cell hybridomas were obtained that could respond to HA(307-319) presented by transgenic, but not by nontransgenic, spleen cells (Fig. 7 A). The DR4Dw4 restriction specificity of these hybridomas was confirmed by demonstrating their ability to respond to antigen presented by stable transformants of the Chinese hamster ovary (CHO) cell line that expressed DR4Dw4. The hybridomas could also respond to antigen presented by the DR4Dw4-positive EBV transformed B cell line, Priess, or by PBLS isolated from a DR4Dw4-positive individual.

These transgenic mice can be used to raise DR4Dw4-restricted T cells specific for any immunogenic antigen, including human proteins. For instance, DR4Dw4-restricted mouse T cell hybridomas specific for human serum albumin have been generated from these mice (Fig. 7 B). These hybridomas could respond to freshly isolated human PBLS from a DR4Dw4-positive individual without the addition of exogenous antigen.

**Discussion**

Recombinant gene constructions in which sequences encoding the human DR4Dw4 peptide-binding domain were spliced onto the mouse Ea gene were used to create transgenic mice that were capable of generating human MHC class II-restricted T cell responses. The DR4Dw4-derived peptide-binding domain of the chimeric class II molecules appeared to be folded into a proper conformation since these molecules: (a) were recognized by a panel of DR-specific mAbs; (b) could bind DR-restricted peptides with similar affinities to those of native DR4Dw4; and (c) could present antigen to a DR4Dw4-restricted human T cell clone. Thus, the α1/β1 peptide-binding domain may fold somewhat independently of the rest of the class II molecule.

The chimeric class II molecules are fully functional as antigen-presenting molecules in the transgenic mice as demonstrated by the generation of DR4Dw4-restricted T cell responses after immunization with peptide or whole protein antigens. This demonstrates that the repertoire of mouse TCRs is sufficiently diverse to allow for the selection of human MHC
Figure 6. Lymph node proliferative responses in chimeric MHC class II transgenic mice. Antigen-recall responses to (A) HA(307-319) and (B) PPD are shown for a transgenic mouse and a nontransgenic littermate. MHC class II blocking Abs specific for A1 (Y3P) and DR (LB3.1) were added where indicated. Blocking Abs were added at 10 μg/ml on the first day of culture. The mean counts per minute plus or minus the standard deviation of triplicate wells are shown for HA(307-319) at 100 μM and PPD at 10 μg/ml. The experiment was repeated on five transgenic and five nontransgenic mice with similar results.

class II-restricted T cells. An analogous approach using chimeric MHC class I molecule previously had been used to generate transgenic mice in which human MHC class I-restricted mouse T cell responses could be obtained (35, 36). Human class I-restricted cytotoxic T cell clones could be raised from these animals after challenge with viral antigens.

Chimeric class II transgenic animal could be used to generate antigen-specific, DR4w4-restricted mouse T cell hybridomas. These are valuable reagents that cannot be generated directly from human T cell clones using current technology. Moreover, DR4-Dw4-restricted T cells specific for any immunogenic human protein can be obtained from these animals. Consequently, these mice can be used to generate human self-antigen-reactive T cell clones that could not be raised directly from humans because of ethical considerations and because of tolerance to self-antigens. As an example, DR4-Dw4-restricted, human serum albumin–specific T cells were raised, and these cells responded to PBLs from DR4-Dw4-positive individuals without the necessity of adding exogenous albumin to the cultures. This demonstrates that human APCs can constitutively process serum proteins which can then associate with class II molecules. This is consistent with the results reported by Panina et al. (37) in which a human alloreactive clone was shown to be specific for a peptide derived from human serum albumin.

Superantigen-reactive, Vβ11-expressing T cells were deleted in transgenic mice expressing chimeric class II molecules. This result extends the previous observation that DRα/β interspecies heterodimers can cause superantigen-mediated T cell clonal deletion in transgenic mice (38). Chimeric α/β or Eα/chimeric β chain heterodimers are not expressed in the transgenic mice since the founders were crossed onto an Eα/Eβ-negative H-2b MHC haplotype. The presence of chimeric α/β or α/α/chimeric β chain heterodimers in the transgenic mice is unlikely as lymphocytes from H-2b homozygous transgenic mice that contained only the chimeric α or β chain transgene did not bind to any of the DR-specific mAbs tested. Thus, deletion of superantigen-reactive Vβ11-expressing T cells in the transgenic mice was mediated by chimeric α/β chain heterodimers. It is not clear to what extent the human and mouse sequences in the chimeric class II MHC molecules contributed to this deletion phenomenon.

The fact that the chimeric class II molecules were functional in transgenic mice is consistent with the location of a CD4-binding site on the α2 and/or β2 domains of class
II molecules. However, we have not directly demonstrated the interaction of mouse CD4 with these domains. It is possible that the presence of the mouse α2/β2 domains contributes to the functionality of the chimeric class II molecules in transgenic mice for other unknown reasons. Mouse CD4-positive DR4 Dw4-restricted T cell hybridomas were capable of responding to antigen presented by human class II-positive cells despite the inefficiency of mouse CD4–human class II interactions. It is possible that these T cell responses are suboptimal and might be enhanced by the expression of human CD4 in the T cell hybridoma lines.

The transgenic mice described in this report are fertile, appear healthy, and have not displayed any spontaneous pathology, despite the association of DR4 Dw4 with autoimmune disease in humans. Since susceptibility to autoimmune disease is determined by multiple genetic factors, it will be of interest to backcross the transgenic mice to other inbred strains of mice. The role of DR4 Dw4 molecules in autoimmune disease induced by active immunization with potential autoantigens such as collagen type II can also be evaluated using these transgenic mice.

In summary, we have developed a transgenic mouse model in which human DR-restricted immune responses can be obtained. These mice offer a powerful model system in which DR4 Dw4-restricted antigenic determinants can be identified and in which therapeutic agents that affect DR-restricted immune responses can be evaluated. These mice should be useful for studying the mechanism by which particular DR alleles are associated with specific human autoimmune diseases.

We thank Alison Pressey and Rose Cubbon for assistance with the MHC class II binding assays; and Michael Tocci, Jeff Hermes, Phyllis Whiteley, and Linda Wicker for critically reading the manuscript.

Address correspondence to Dr. D. M. Zaller, Department of Molecular Immunology, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065.

Received for publication 29 November 1993 and in revised form 16 March 1994.
References

1. Nepom, G.T., and H. Erlich. 1991. MHC class-II molecules and autoimmunity. *Annu. Rev. Immunol.* 9:493.

2. Tiraw, J., and P. Terasaki. 1985. HLA and Disease Associations. Springer-Verlag New York Inc., New York. 472 pp.

3. Oldstone, M.B. 1987. Molecular mimicry and autoimmune disease. *Cell.* 50:819.

4. Oldstone, M.B. 1989. Molecular mimicry as a mechanism for the cause and a probe uncovering etiologic agent(s) of autoimmune disease. *Curr. Top. Microbiol. Immunol.* 145:127.

5. Fujinami, R.S., J.A. Nelson, L. Walker, and M.B. Oldstone. 1988. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. *J. Virol.* 62:100.

6. Horn, G.T., T.L. Bugawan, C.M. Long, and H.A. Erlich. 1988. Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility. *Proc. Natl. Acad. Sci. USA.* 85:6012.

7. Roudier, J., G. Rhodes, J. Petersen, J.H. Vaughan, and D.A. Carson. 1988. The Epstein-Barr virus glycoprotein gp10, a molecular link between DR4, HLA DR1, and rheumatoid arthritis. *Scand. J. Immunol.* 27:367.

8. Sasazuki, T., T. Iwashita, T. Inamitsu, Y. Yanagawa, M. Yasunami, A. Kimura, K. Hirokawa, and Y. Nishimura. 1989. Expression and function of human major histocompatibility complex HLA-DQw6 genes in the C57BL/6 mouse. *Cold Spring Harbor Symp. Quant. Biol.* 1:513.

9. Nishimura, Y., T. Iwashita, T. Inamitsu, Y. Yanagawa, M. Yasunami, A. Kimura, K. Hirokawa, and T. Sasazuki. 1990. Expression of the human MHC HLA-DQw6 genes alters the immune response in C57BL/6 mice. *J. Immunol.* 145:353.

10. Slackman, B.P., A. Peterson, W.K. Jones, J.A. Foran, J.L. Greenstein, B. Seed, and S.J. Burakoff. 1987. Expression and function of CD4 in a murine T cell hybridoma. *Nature (Lond.)* 328:351.

11. Lamarre, D., A. Ashkenazi, S. Fleury, D.H. Smith, R.P. Sekaly, and T. Fournier. 1987. The Epstein-Barr virus glycoprotein gp10, a molecular link between DR4, HLA DR1, and rheumatoid arthritis. *Scand. J. Immunol.* 27:367.

12. Lombardi, G., L. Barber, G. Aichinger, T. Heaton, S. Sidhu, J.R. Batchelor, and R.I. Lechler. 1991. Structural analysis of anti-DR1 allelerecognition by using DR1/H-2Kb hybrid molecules. Influence of the beta 2-domain correlates with CD4 dependence. *J. Immunol.* 147:2034.

13. Vignali, D.A.A., J. Moreno, D. Schiller, and G.J. Hammerling. 1992. Species-specific binding of CD4 to the beta 2 domain of major histocompatibility complex class II molecules. *J. Exp. Med.* 175:925.

14. Konig, R., I.Y. Huang, and R.N. Germain. 1992. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. *Nature (Lond.)* 356:796.

15. Cammarota, G., A. Scheirle, B. Takacs, D.M. Doran, R. Knorr, W. Bannwarth, J. Guardiola, and F. Sinigaglia. 1992. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. *Nature (Lond.)* 356:799.

16. Nepom, G.T., J. Hansen, and B. Nepom. 1986. The molecular basis for HLA class II associations with rheumatoid arthritis. *J. Clin. Immunol.* 7:1.

17. Stasny, P. 1978. Associations of the B-cell alloantigen Dw4 with rheumatoid arthritis. *N. Engl. J. Med.* 289:869.

18. Nepom, B.S., G.T. Nepom, J. Schaller, E. Mickelson, J. Schaller, P. Antonelli, and A. Hansen. 1984. Specific HLA-DR4-associated histocompatibility molecules in patients with seropositive juvenile rheumatoid arthritis. *J. Clin. Invest.* 74:287.

19. Zoschke, D., and M. Segall. 1986. Dw subtypes of DR4 in rheumatoid arthritis: evidence for a preferential association with Dw4. *Hum. Immunol.* 15:118.

20. Ollier, W., D. Carthy, S. Cutbush, R. Ookay, J. Awad, J. Fielder, A. Silman, and H. Festenstein. 1988. DR4-associated Dw types in rheumatoid arthritis. *Tissue Antigens.* 33:33.

21. Nepom, G.T., P. Byers, C. Seyfried, L.A. Healey, K.R. W'dske, J. Tait, B.D., G. Mraz, and L.C. Harrison. 1988. Association of HLA-DQw3 (TA10-) with type I diabetes occurs with DR3/4 but not DR1/4 patients. *Diabetes.* 37:926.

22. Sheehy, M.J., J.S. Scharf, J.R. Rowe, M.H. Neme de Gimenez, L.M. Meske, H.A. Erlich, and B.S. Nepom. 1989. A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles. *J. Clin. Invest.* 83:830.

23. Erlich, H.A., T.L. Bugawan, S. Scharf, G.T. Nepom, B. Tait, and R.L. Griffith. 1990. HLA-DQ beta sequence polymorphism and genetic susceptibility to IDDM. *Diabetes.* 39:96.

24. Anderson, G., D. Latham, E. Widmark, B. Servenius, P.A. Peterson, and L. Rask. 1987. Class II genes of the human major histocompatibility complex. Organization and evolutionary relationship of the DR beta genes (published erratum appears in *J. Biol. Chem.* 1988. Jun 15;263[17]:8551). *J. Biol. Chem.* 262:7848.

25. Kim, K.J., C. Kannelopoulos-Langerin, R.M. Merwin, D.H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. *J. Immunol.* 122:549.

26. White, J., M. Blackman, J. Bill, J. Kappler, P. Marrack, D.P. Gold, and W. Born. 1989. Two better cell lines for making hybridomas expressing specific T cell receptors. *J. Immunol.* 143:1822.

27. Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. *Annu. Rev. Immunol.* 8:681.

28. Dorn, A., B. Durand, C. Marfig, M.M. Le, C. Benoist, and D. Mathis. 1987. Conserved major histocompatibility complex class II boxes—X and Y—are transcriptional control elements and specifically bind nuclear proteins. *Proc. Natl. Acad. Sci. USA.* 84:6249.

29. Gao, E.-K., O. Kanagawa, and S. Sprent. 1989. Capacity of unprimed CD4+ and CD8+ T cells expressing Vβ11 receptors to respond to I-E alloantigens in vivo. *J. Exp. Med.* 170:1947.

30. Salter, R.D., R.J. Benjamin, and P.P. Jones. 1989. Molecular defects in the non-expressed H-2 E alpha genes of the MHC. *Nature (Lond.)* 356:796.

31. Bill, J., O. Kanagawa, D.L. Woodward, and E. Palmer. 1989. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of Vβ11-bearing T cells. *J. Exp. Med.* 169:1405.

32. Begovich, A.B., T.H. Vu, and P.P. Jones. 1990. Characterization of the molecular defects in the mouse E beta f and E beta 2 q haplotypes. *J. Immunol.* 142:2936.

33. Bill, J., and P.P. Jones. 1989. Capacity of unprimed CD4+ and CD8+ T cells expressing Vβ11 receptors to respond to I-E alloantigens in vivo. *J. Exp. Med.* 170:1947.

34. Salter, R.D., R.J. Benjamin, P.P. Jones, and E. Buxton, T.P.
Garrett, C. Clayberger, A.M. Krensky, A.M. Norment, D.R. Littman, and P. Parham. 1990. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. *Nature (Lond.)* 345:41.

36. Vitiello, A., D. Marchesini, J. Furze, L.A. Sherman, and R.W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. *J. Exp. Med.* 173:1007.

37. Panina, B.P., G. Corradin, E. Roosnek, A. Sette, and A. Lan- zavecchia. 1991. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. *Science (Wash. DC)*. 252:1548.

38. Lawrance, S.K., L. Karlsson, J. Price, V. Quaranta, Y. Ron, J. Sprent, and P.A. Peterson. 1989. Transgenic HLA-DR alpha faithfully reconstitutes IE-controlled immune functions and induces cross-tolerance to E alpha and E alpha 0 mutant mice. *Cell.* 58:583.